Mono-Linyah

Acne Vulgaris, moderate Vulvovaginal atrophy, Hot flashes + 9 more

Treatment

9 FDA approvals

20 Active Studies for Mono-Linyah

What is Mono-Linyah

Norgestimate

The Generic name of this drug

Treatment Summary

Ethinylestradiol is a synthetic form of estrogen that was developed in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering. It was created to be more bioavailable when taken orally, and eventually replaced mestranol in contraceptive pills. The FDA approved ethinylestradiol in 1943.

Ortho Tri Cyclen

is the brand name

image of different drug pills on a surface

Mono-Linyah Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Ortho Tri Cyclen

Norgestimate

1989

113

Approved as Treatment by the FDA

Norgestimate, commonly known as Ortho Tri Cyclen, is approved by the FDA for 9 uses which include Postmenopausal Osteoporosis and severe menopausal vulvovaginal atrophy .

Postmenopausal Osteoporosis

Used to treat Postmenopausal Osteoporosis in combination with Estradiol

severe menopausal vulvovaginal atrophy

Used to treat severe menopausal vulvovaginal atrophy in combination with Estradiol

Oral Contraceptives

Used to treat Oral Contraceptives in combination with Ethinylestradiol

Acne Vulgaris

Used to treat moderate Acne vulgaris in combination with Ethinylestradiol

Osteoporosis, Postmenopausal

Used to treat Postmenopausal Osteoporosis in combination with Estradiol

moderate Vulvovaginal atrophy

Used to treat moderate Vulvovaginal atrophy in combination with Estradiol

Hot flashes

Used to treat Menopause in combination with Estradiol

moderate Menopausal Vasomotor Symptoms

Used to treat moderate Menopausal Vasomotor Symptoms in combination with Estradiol

Menopause

Used to treat severe Vasomotor Symptoms Associated With Menopause in combination with Estradiol

Effectiveness

How Mono-Linyah Affects Patients

Ethinylestradiol is a synthetic form of estrogen that stops the body from releasing hormones that cause ovulation, and reduces the development of blood vessels in the uterus. This drug has a long lasting effect and is generally safe, although it can increase the risk of blood clots. Patients should be informed of this risk before taking the medication.

How Mono-Linyah works in the body

Ethinylestradiol is a synthetic form of the hormone estrogen. It is used in combined oral contraceptives to stop ovulation, thickening cervical mucus to block sperm, and prevent changes in the uterus that could lead to pregnancy. Ethinylestradiol also keeps the uterus from becoming too vascular and increases a protein that binds to hormones in the body.

When to interrupt dosage

The recommended dosage of Mono-Linyah is contingent upon the established condition, including Acne Vulgaris, Hormonal Contraception and Folate supplementation therapy. The measure of dosage diverges, in relation to the mode of delivery as specified in the table below.

Condition

Dosage

Administration

Oral Contraceptives

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Polycystic Ovarian Syndrome

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

moderate Vulvovaginal atrophy

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

severe menopausal vulvovaginal atrophy

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Menopause

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Osteoporosis, Postmenopausal

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Menorrhagia

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Hirsutism

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

moderate Menopausal Vasomotor Symptoms

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Hot flashes

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Acne Vulgaris

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Dysmenorrhea

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Warnings

Mono-Linyah has twenty-six contraindications and should not be taken concurrently with any of the circumstances detailed in the table below.

Mono-Linyah Contraindications

Condition

Risk Level

Notes

Breast

Do Not Combine

Breast Cancer

Do Not Combine

high risk of arterial thrombotic disease

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Hypersensitivity

Do Not Combine

Venous Thrombosis

Do Not Combine

Pulse Frequency

Do Not Combine

estrogen-sensitive cancer

Do Not Combine

Metrorrhagia

Do Not Combine

Liver Neoplasms

Do Not Combine

There are 20 known major drug interactions with Mono-Linyah.

Common Mono-Linyah Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Norgestimate.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Norgestimate.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Norgestimate.

Aminophylline

Major

The metabolism of Aminophylline can be increased when combined with Norgestimate.

Astemizole

Major

The metabolism of Astemizole can be increased when combined with Norgestimate.

Mono-Linyah Toxicity & Overdose Risk

Women who overdose on birth control may experience irregular bleeding, nausea, vomiting, tenderness in the breasts, abdominal pain, drowsiness, and fatigue. Treatment for overdose should include monitoring of electrolyte levels and signs of metabolic acidosis, as well as providing supportive care.

Mono-Linyah Novel Uses: Which Conditions Have a Clinical Trial Featuring Mono-Linyah?

There are 38 clinical trials in progress to assess the potential of Mono-Linyah to provide Folate supplementation therapy, alleviate Premenstrual Dysphoric Disorder and address the symptoms of Menopause.

Condition

Clinical Trials

Trial Phases

Dysmenorrhea

0 Actively Recruiting

Acne Vulgaris

0 Actively Recruiting

Osteoporosis, Postmenopausal

0 Actively Recruiting

Oral Contraceptives

0 Actively Recruiting

Menopause

0 Actively Recruiting

Polycystic Ovarian Syndrome

9 Actively Recruiting

Phase 1, Not Applicable

moderate Menopausal Vasomotor Symptoms

0 Actively Recruiting

Hirsutism

0 Actively Recruiting

Hot flashes

30 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3, Phase 1

moderate Vulvovaginal atrophy

0 Actively Recruiting

Menorrhagia

0 Actively Recruiting

severe menopausal vulvovaginal atrophy

0 Actively Recruiting

Mono-Linyah Reviews: What are patients saying about Mono-Linyah?

4.7

Patient Review

1/13/2020

Mono-Linyah for Acne

I went with Mono-Linyah to treat my acne and it's been great. At the beginning, my hormones were all over the place which led to some anxiety. However, after four months things evened out and now my skin is almost completely clear. I've had no other side effects besides slightly worse cramping during my period and larger breasts.

4.7

Patient Review

4/7/2021

Mono-Linyah for Birth Control

I've been pleased with this birth control so far. It caused a bit of nausea at first (but that went away), and my breasts are now sore. Otherwise, I haven't had any real negative reactions like mood swings. I'm also not spotting, which is great since I was on the mini pill before and getting a period every two weeks.

4.7

Patient Review

7/11/2018

Mono-Linyah for Birth Control

I haven't had any issues with side effects and my periods have been regular. The packaging could be better, but it's not a big deal. I'm just glad the medication works.

4.3

Patient Review

6/11/2018

Mono-Linyah for Acne

This birth control has done wonders for my acne. I haven't had any negative side effects that I can speak of and my skin has never looked better.

4.3

Patient Review

5/21/2022

Mono-Linyah for Painful Periods

This birth control has been great in terms of preventing cramps and other period side effects. However, it's worth noting that it's had negative impacts on my mental health. Overall, though, it's manageable.

4

Patient Review

11/26/2021

Mono-Linyah for Painful Periods

I was extremely pleased with how this medication alleviated my PCOS symptoms; however, I experienced prolonged bleeding which became quite burdensome.

4

Patient Review

5/14/2018

Mono-Linyah for Birth Control

The medication works well, but the packaging is very difficult to use. I've lost pills because of this before, which is frustrating.

3

Patient Review

2/6/2019

Mono-Linyah for Birth Control

I was taking spryntec for a while, but when I changed pharmacists they switched me to this. It does its job well enough, but I constantly feel nauseous and grossed out. I stopped taking it and went back to the doctor.

2.7

Patient Review

5/4/2022

Mono-Linyah for Painful Periods

This medication helps with my periods, but unfortunately I've had more migraines since taking it. For me, the pros don't outweigh the cons.

Patient Q&A Section about mono-linyah

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What kind of birth control is Mono-Linyah?

"Mono-Linyah is a birth control pill that contains two different hormones: norgestimate (a progestin) and ethinyl estradiol (an estrogen)."

Answered by AI

What is Mono-Linyah generic for?

"Mono-Linyah is a generic birth control pill for women. The hormones in Mono-Linyah, norgestimate and ethinyl estradiol, prevent ovulation and change the cervical and uterine linings to block the movement of sperm and prevent implantation of a fertilized egg."

Answered by AI

What are the side effects of Mono-Linyah birth control?

"The following side effects may occur: nausea, vomiting, headache, bloating, breast tenderness, swelling of the ankles/feet (fluid retention), or weight change. Vaginal bleeding between periods (spotting) or missed/irregular periods may occur, especially during the first few months of use."

Answered by AI

Is Mono-Linyah a good birth control?

"While Mono-Linyah is not 100% effective, it is a safe and effective method of birth control when used properly. If you miss a dose or are late taking your medication, use backup birth control until your next cycle to ensure you are fully protected."

Answered by AI

Clinical Trials for Mono-Linyah

Image of St. Joseph's Healthcare Hamilton in Hamilton, Canada.

Internet-Delivered Cognitive Behavioural Therapy for Hot Flashes

40 - 60
Female
Hamilton, Canada

Given the impact that hot flashes and night sweats can have on daily life during the menopausal transition, our team has developed a therapist-guided online cognitive behavioural therapy (CBT)- based program to help individuals manage these symptoms. An online program may help address systemic barriers to in-person care, such as cost, time, travel, and caregiving needs. The broad aim of this pilot clinical trial is to examine the experience of a four-week therapist-guided online CBT-based program for menopause-related hot flashes and night sweats. The primary objective of this study is to evaluate the acceptability and feasibility of the four-week online program, including how participants experience the program and how well they are able to complete it at home. The secondary objective is to explore whether the program may help with hot flashes and night sweats, and related concerns such as sleep, mood, anxiety, and quality of life. Exploratory analyses will examine whether changes in these outcomes are maintained three months after completing the program. Researchers will compare participants who receive the program immediately with participants who wait four weeks before receiving it. Participants will: * Complete online questionnaires about their symptoms and well-being. * Complete four weekly online lessons and activities. * Meet briefly with a guide each week for guidance and support. * Complete follow-up questionnaires after the program and three months later.

Waitlist Available
Has No Placebo

St. Joseph's Healthcare Hamilton

Sheryl M Green, PhD, CPsych

Image of MusB Research LLC in New Port Richey, United States.

Ashoka Bark and Shatavari for Menopause

40 - 65
Female
New Port Richey, FL

This 12-week randomized, placebo-controlled clinical trial will evaluate the efficacy and safety of a daily oral supplement containing Ashoka Bark and Shatavari in women experiencing menopausal symptoms. Up to 50 participants will be randomized to receive either the active supplement or placebo, with 40 participants expected to complete the study. Participants will attend visits at Weeks 0, 6, and 12, where hormone levels (FSH and estradiol), menopausal symptoms, quality of life, anxiety, cognitive function, and sleep will be assessed using validated measures. The study will also explore changes in the vaginal microbiome and monitor safety and adherence throughout the trial. The study will be conducted at MusB Research in New Port Richey, Florida.

Recruiting
New This Month

MusB Research LLC

Vidya USA Corporation

Image of Alberta Diabetes Institute in Edmonton, Canada.

Resistance Exercise for Type 1 Diabetes

18+
Female
Edmonton, Canada

Improvements in diabetes care and technology have led to people with type 1 diabetes living longer. There are now more seniors than ever living with this complex health condition. With aging, type 1 diabetes affects both bone (more brittle), and muscle (loss of size and strength). This loss happens faster and to a greater extent in females than in males, and greatly increases the risk of frailty and falls. It may also occur more quickly in individuals who have higher blood glucose (sugar) levels. Frailty is an important factor to address. In older females, even mild frailty decreases the ability to perform day-to-day tasks, and increases the risk of fractures, falls, hospitalization, and even death. Performing regular exercise helps to maintain the strength and quality of both muscles and bones with aging. The best type of exercise to help maintain the ability to perform activities of daily living (known as functional mobility) for this population is currently unknown. Resistance exercise (weightlifting) helps to prevent decreases in mobility in seniors without diabetes. However, in the context of type 1 diabetes, high blood sugar levels could negatively impact these potential strength benefits and low blood glucose could lead to falls. As such, any exercise program that causes swings in glucose levels may hinder rather than help. The goal of this study is to evaluate the effect of weightlifting over a 6-month timeframe on functional mobility in postmenopausal females with type 1 diabetes, compared to a group that does not train. the investigators will also assess its effects on blood sugar variability and the risk of hypoglycemia. Like different medications, not all exercise is equal. Creating more knowledge about the benefits of specific types of exercise in this population will allow us to be more precise in our exercise recommendations for living longer and more independently with type 1 diabetes.

Waitlist Available
Has No Placebo

Alberta Diabetes Institute (+2 Sites)

Jane E Yardley, PhD

Have you considered Mono-Linyah clinical trials?

We made a collection of clinical trials featuring Mono-Linyah, we think they might fit your search criteria.
Go to Trials
Image of Novum Pharmaceutical Research Services in Las Vegas, United States.

Estradiol/Levonorgestrel Patch for Menopause

40 - 75
Female
Las Vegas, NV

The two products used in this study are transdermal patches that contain selegiline. The test drug is the Estradiol/Levonorgestrel Transdermal Delivery System (TDS). The comparator drug is the Climara Pro® TDS. The purpose of this research study is to compare how the skin tolerates the test TDS and the comparator TDS. The study will evaluate and compare skin irritation and possible allergic-type skin reactions (sensitization) caused by the two products. The comparison will be based on how the skin responds to repeated applications of each TDS. This includes the assessment of skin irritation during the Induction Period and the evaluation of possible allergic or sensitization reactions after the Challenge Period. In addition, the adhesion of each patch (how well the patch sticks to the skin over time) will be regularly checked, as this is important for both product performance and skin safety.

Phase 1
Recruiting

Novum Pharmaceutical Research Services

Corium Innovations, Inc.

Image of UNC Fertility in Raleigh, United States.

Exemestane for Polycystic Ovarian Syndrome

18 - 40
Female
Raleigh, NC

The goal of this clinical trial is to learn if study drug exemestane will increase chances of ovulation for patients with polyendocrine metabolic ovarian syndrome (PMOS, formerly called polycystic ovary syndrome (PCOS)). It will also learn about side effects of study drug exemestane in this study population. The main questions it aims to answer are: Does exemestane lead to ovulation for patients with polyendocrine metabolic ovarian syndrome (PMOS- formerly called PCOS)? Researchers will compare exemestane to a placebo (a look-alike substance that contains no drug) to see if exemestane helps PMOS patients ovulate. Participants will: Take exemestane or a placebo every day for 5-10 days Visit the clinic three times for ultrasounds, labs, and to answer questions about side effects. If they become pregnant during this study, they will tell us how their pregnancy went after the study via a registry online.

Phase 1
Recruiting

UNC Fertility

Bruce Pier, MD

Have you considered Mono-Linyah clinical trials?

We made a collection of clinical trials featuring Mono-Linyah, we think they might fit your search criteria.
Go to Trials
Image of Carnegie Mellon University in Pittsburgh, United States.

Hormonal Effects on Brain Stimulation for Depression

18 - 40
All Sexes
Pittsburgh, PA

This study is investigating how two types of non-invasive brain stimulation, transcranial electrical stimulation (TES) and transcranial magnetic stimulation (TMS), affect brain activity, and whether combining them produces stronger or more consistent effects than either one used alone. The motivation for this comes from the observation that TMS, which is FDA-approved for treating depression, tends to work less well in postmenopausal women because lower estrogen levels reduce the brain's ability to respond to stimulation. The research team believes that pairing TMS with TES, which targets a different set of brain cells, may be able to overcome this hormonal barrier and make stimulation more effective. Participants will come into the lab for up to 24 visits over 8 months, beginning with an initial visit to establish the right stimulation settings, followed by a series of stimulation sessions in which brain activity is measured before and after receiving either TES, TMS, or both together. For female participants, sessions will be scheduled at specific points in the menstrual cycle to capture the natural monthly rise and fall of estrogen, while male participants will be scheduled on a comparable fixed interval as a comparison group. The insights gained from this study could directly inform the development of better, more reliable brain stimulation treatments for women with depression.

Waitlist Available
Has No Placebo

Carnegie Mellon University

Image of The Ohio State University in Columbus, United States.

Mindfulness-Based Group Visits for Menopause

40 - 60
Female
Columbus, OH

While perimenopause and menopause are natural biological transitions, women may experience a wide range of physical, emotional, and cognitive symptoms. Although pharmacological options for symptom relief are available, these options may not be acceptable or suitable for all women. Integrative approaches for symptom relief, offered through group medical visits, may complement traditional therapies by increasing access to providers, allowing more time for focused education, and fostering supportive discussions with other women experiencing similar symptoms of perimenopause or menopause. The purpose of this study is to assess the effectiveness of eight monthly group medical visits that incorporate individual physical assessments, focused education on the foundational elements of Lifestyle Medicine relative to health and well-being, mindfulness practices, and community-building discussions with women experiencing perimenopause or menopause. Individual outcomes, obtained before the group medical visits begin, at each monthly group medical visit, and four months after the group medical visits are completed, will include measures of participants' perimenopause or menopause symptoms, stress, inflammation, microbiome (good bacteria in the body), height/weight, body mass index (BMI), systolic and diastolic blood pressure, and self-reported perceptions of physical, mental, and social health. Each 120-minute monthly group medical visit, led by a specially trained nurse practitioner and a mindfulness instructor, will include a brief physical assessment, educational discussions related to menopause and lifestyle medicine, experiential mindfulness practices, and the development of individual health and well-being goals.

Waitlist Available
Has No Placebo

The Ohio State University

Have you considered Mono-Linyah clinical trials?

We made a collection of clinical trials featuring Mono-Linyah, we think they might fit your search criteria.
Go to Trials